Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Glaxo Wellcome UK Ltd. trading as GlaxoSmithKline UK., 980 Great West Road, Brentford, Middlesex, TW8 9GS
Imigran 50mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. 50 mg tablet: Pink, film-coated, capsule-shaped, biconvex tablet (of nominal dimensions: 12 mm x 6.5 mm), engraved “50” on one face and plain on the other face. |
50mg sumatriptan base as the succinate salt.
Excipient with known effect:
70 mg lactose monohydrate/tablet.
140 mg lactose/tablet.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Sumatriptan |
Sumatriptan has been demonstrated to be a specific and selective 5-Hydroxytryptamine1 (5HT1D) receptor agonist with no effect on other 5HT receptor (5-HT2 - 5-HT7) subtypes. The vascular 5-HT1D receptor is found predominantly in cranial blood vessels and mediates vasoconstriction. |
| List of Excipients |
|---|
|
Lactose monohydrate |
Aluminium double foil blister pack or child-resistant foil blister pack in a cardboard carton, containing either 2, 3, 6, 12, 18 or 24 tablets.
Glaxo Wellcome UK Ltd. trading as GlaxoSmithKline UK., 980 Great West Road, Brentford, Middlesex, TW8 9GS
PL 10949/0222
29/12/2005
| Drug | Countries | |
|---|---|---|
| IMIGRAN | Austria, Australia, Brazil, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, Hong Kong, Croatia, Ireland, Italy, Japan, Lithuania, Malta, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
